GlassScriptPhysician profile
Charles J Franson
NPI 1285707828
$4,366.93
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $525 · 2021: $1,030 · 2022: $445 · 2023: $998 · 2024: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,416.56 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $775.32 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $350.95 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.88 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $213.23 | 2019-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $175.50 | 2020-2022 | |
| Corcept Therapeutics | $153.93 | 2023-2024 | Korlym |
| Glaxosmithkline, LLC. | $144.70 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $137.77 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $130.49 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $95.30 | 2020-2021 | |
| Astellas Pharma US INC | $70.67 | 2019-2024 | Veozah |
| Allergan, INC. | $67.06 | 2019-2020 | |
| Amgen INC. | $64.31 | 2023-2024 | Otezla, Repatha |
| Radius Health, INC. | $57.42 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $57.22 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $47.27 | 2024 | |
| Janssen Pharmaceuticals, INC | $42.54 | 2019-2020 | |
| Genentech USA, INC. | $31.20 | 2019 | |
| Exact Sciences Corporation | $27.47 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $25.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.85 | 2022 | |
| Horizon Therapeutics Plc | $16.21 | 2021 | |
| Inogen, INC. | $12.02 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Franson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.